Affinity-enhanced T-cell receptor (TCR) NK cell therapy targeting NY-ESO-1
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Affinity-enhanced T-cell receptor (TCR) NK cell therapy targeting NY-ESO-1, covering 2026-04-16 to 2026-04-16. Get the full timeline:
Most recent: Clinical Trial Update: Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 [Phase 1]